Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker ASND
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Bodenhoff Mads Officer | ASND Ascendis Pharma A/S | 3,000 | $810.6K | — | Sep 8, 2026 | Form 4 ↗ 1 day later · 3,000 shares | Form 144 ↗ |
| Sep 2, 2026 | Holtug Lars Director | ASND Ascendis Pharma A/S | 236 | $62.3K | — | Sep 2, 2026 | Form 4 ↗ 1 day later · 236 shares | Form 144 ↗ |
| May 11, 2026 | Jensen Flemming Steen Officer, EXECUTIVE VP HEAD OF PRODUCT S… | ASND Ascendis Pharma A/S | 19,460 | $4.6M | — | May 11, 2026 | Form 4 ↗ 1 day later · 19,460 shares | Form 144 ↗ |
| Mar 9, 2026 | Singel Stina Officer | ASND Ascendis Pharma A/S | 3,782 | $907.7K | — | Mar 9, 2026 | — | Form 144 ↗ |
| Mar 6, 2026 | Bodenhoff Mads Officer | ASND Ascendis Pharma A/S | 10,000 | $2.4M | — | Mar 6, 2026 | — | Form 144 ↗ |
| Mar 6, 2026 amended | Smith Scott Thomas Officer | ASND Ascendis Pharma A/S | 10,000 | $2.4M | — | Mar 5, 2026 | — | Form 144/A ↗ |
| Mar 5, 2026 | Jan Moller Mikkelsen CEO, Officer | ASND Ascendis Pharma A/S | 94,000 | $22.7M | — | Mar 5, 2026 | — | Form 144 ↗ |
| Mar 5, 2026 | Shu Aimee Officer | ASND Ascendis Pharma A/S | 5,583 | $1.3M | — | Mar 5, 2026 | — | Form 144 ↗ |
| Mar 5, 2026 | Smith Scott Thomas Officer | ASND Ascendis Pharma A/S | 10,000 | $2.4M | — | Mar 5, 2026 | — | Form 144 ↗ |
| Mar 4, 2026 | Shu Aimee Officer, EXECUTIVE VICE PRESIDENT CHIEF… | ASND Ascendis Pharma A/S | 7,290 | $1.7M | — | Mar 4, 2026 | — | Form 144 ↗ |
| Mar 4, 2026 | Lisa Morrison Officer | ASND Ascendis Pharma A/S | 10,105 | $2.4M | — | Mar 4, 2026 | — | Form 144 ↗ |
| Mar 2, 2026 | William Fairey Director | ASND Ascendis Pharma A/S | 1,800 | $435.8K | 10b5-1 | Mar 2, 2026 | — | Form 144 ↗ |
| Mar 2, 2026 | Imani Siham Director | ASND Ascendis Pharma A/S | 1,800 | $435.8K | 10b5-1 | Mar 2, 2026 | — | Form 144 ↗ |
| Mar 2, 2026 | Smith Scott Thomas Officer, EXECUTIVE VP CHIEF FINANCIAL O… | ASND Ascendis Pharma A/S | 18,349 | $4.4M | 10b5-1 | Mar 2, 2026 | — | Form 144 ↗ |
| Mar 2, 2026 | Jensen Michael Wolff Officer, EXECUTUVE VP CHIEF LEGAL OFFIC… | ASND Ascendis Pharma A/S | 18,349 | $4.4M | 10b5-1 | Mar 2, 2026 | — | Form 144 ↗ |
| Mar 2, 2026 | Bodenhoff Mads Officer, SENIOR VP PRINCIPAL ACCOUNTING… | ASND Ascendis Pharma A/S | 6,872 | $1.7M | 10b5-1 | Mar 2, 2026 | — | Form 144 ↗ |
| Mar 2, 2026 | Pedersen Anni Lotte Kirstine Sonderbjerg Officer, EXECUTIVE VP CHIEF ADMINISTRAT… | ASND Ascendis Pharma A/S | 10,800 | $2.6M | 10b5-1 | Mar 2, 2026 | — | Form 144 ↗ |
| Mar 2, 2026 | Lisa Morrison Director | ASND Ascendis Pharma A/S | 2,100 | $508.4K | 10b5-1 | Mar 2, 2026 | — | Form 144 ↗ |
| Mar 2, 2026 | Holtug Lars Director | ASND Ascendis Pharma A/S | 2,100 | $508.4K | 10b5-1 | Mar 2, 2026 | — | Form 144 ↗ |
| Mar 2, 2026 | Sprogoe Kennett Officer, EXECUTIVE VP HEAD OF RESEARCH… | ASND Ascendis Pharma A/S | 10,800 | $2.6M | 10b5-1 | Mar 2, 2026 | — | Form 144 ↗ |
| Mar 2, 2026 | Jensen Flemming Steen Officer, EXECUTIVE VP HEAD OF PRODUCT S… | ASND Ascendis Pharma A/S | 10,800 | $2.6M | 10b5-1 | Mar 2, 2026 | Form 4 ↗ 71 days later · 19,460 shares | Form 144 ↗ |
| Mar 2, 2026 | Albert Cha Director | ASND Ascendis Pharma A/S | 2,100 | $508.4K | 10b5-1 | Mar 2, 2026 | — | Form 144 ↗ |
| Jan 13, 2026 | Mikkelsen Jan Moller Officer, PRESIDENT CEO | ASND Ascendis Pharma A/S | 86,860 | $18.4M | 10b5-1 | Jan 13, 2026 | — | Form 144 ↗ |
| Dec 4, 2025 | Jensen Michael Wolff Officer | ASND Ascendis Pharma A/S | 10,000 | $2.1M | — | Dec 4, 2025 | — | Form 144 ↗ |
| Dec 2, 2025 | Jan Moller Mikkelsen CEO, Officer | ASND Ascendis Pharma A/S | 100,000 | $21.1M | — | Dec 2, 2025 | — | Form 144 ↗ |
| Dec 2, 2025 | Sprogoe Kennett Officer | ASND Ascendis Pharma A/S | 10,000 | $2.1M | — | Dec 2, 2025 | — | Form 144 ↗ |
| Dec 2, 2025 | Jensen Flemming Steen Officer | ASND Ascendis Pharma A/S | 10,000 | $2.1M | — | Dec 2, 2025 | — | Form 144 ↗ |
| Dec 1, 2025 | Singel Stina Officer | ASND Ascendis Pharma A/S | 218 | $45.7K | — | Dec 1, 2025 | — | Form 144 ↗ |
| Sep 9, 2025 | Jensen Flemming Steen Officer | ASND Ascendis Pharma A/S | 5,000 | $1.0M | — | Sep 9, 2025 | — | Form 144 ↗ |
| Aug 29, 2025 | Jensen Michael Wolff Officer | ASND Ascendis Pharma A/S | 5,000 | $965.0K | — | Aug 29, 2025 | — | Form 144 ↗ |
| Aug 27, 2025 | Pedersen Anni Lotte Kirstine Sonderbjerg Officer | ASND Ascendis Pharma A/S | 3,036 | $588.8K | — | Aug 27, 2025 | — | Form 144 ↗ |
| Aug 20, 2025 | Jan Moller Mikkelsen President and Chief Executive Officer | ASND Ascendis Pharma A/S | 3,000 | $578.4K | — | Aug 20, 2025 | — | Form 144 ↗ |
| Aug 15, 2025 | Jensen Michael Wolff Officer | ASND Ascendis Pharma A/S | 9,375 | $1.8M | — | Aug 15, 2025 | — | Form 144 ↗ |
| Aug 14, 2025 | Pedersen Anni Lotte Kirstine Sonderbjerg Officer | ASND Ascendis Pharma A/S | 25,000 | $4.8M | — | Aug 14, 2025 | — | Form 144 ↗ |
| Aug 13, 2025 | Lisa Morrison Director, Non-Executive Director | ASND Ascendis Pharma A/S | 2,158 | $412.3K | — | Aug 13, 2025 | — | Form 144 ↗ |
| Aug 13, 2025 | Jensen Flemming Steen Officer | ASND Ascendis Pharma A/S | 10,000 | $1.9M | — | Aug 13, 2025 | — | Form 144 ↗ |
| Aug 12, 2025 | Smith Scott Thomas Officer | ASND Ascendis Pharma A/S | 10,000 | $1.9M | — | Aug 12, 2025 | — | Form 144 ↗ |
| May 12, 2025 | Shu Aimee Officer, EXECUTIVE VICE PRESIDENT CHIEF… | ASND Ascendis Pharma A/S | 2,018 | $312.4K | — | May 12, 2025 | — | Form 144 ↗ |
| May 7, 2025 | Shu Aimee Officer, EXECUTIVE VICE PRESIDENT CHIEF… | ASND Ascendis Pharma A/S | 4,204 | $700.4K | — | May 6, 2025 | — | Form 144 ↗ |
| May 7, 2025 | Jensen Flemming Steen Officer | ASND Ascendis Pharma A/S | 10,938 | $1.8M | — | May 7, 2025 | — | Form 144 ↗ |
| May 6, 2025 | Sprogoe Kennett Officer | ASND Ascendis Pharma A/S | 10,000 | $1.7M | — | May 6, 2025 | — | Form 144 ↗ |
| May 5, 2025 | Jensen Michael Wolff Officer | ASND Ascendis Pharma A/S | 4,386 | $749.9K | — | May 5, 2025 | — | Form 144 ↗ |
| Mar 7, 2025 | Jensen Michael Wolff Officer | ASND Ascendis Pharma A/S | 4,000 | $585.8K | — | Mar 7, 2025 | — | Form 144 ↗ |
| Mar 6, 2025 | Jensen Flemming Steen Officer | ASND Ascendis Pharma A/S | 10,000 | $1.5M | — | Mar 6, 2025 | — | Form 144 ↗ |
| Mar 6, 2025 | Jensen Michael Wolff Officer | ASND Ascendis Pharma A/S | 1,614 | $245.7K | — | Mar 6, 2025 | — | Form 144 ↗ |
| Mar 5, 2025 | Mikkelsen Jan Moller Officer, PRESIDENT CHIEF EXECUTIVE OFFI… | ASND Ascendis Pharma A/S | 7,789 | $1.2M | 10b5-1 | Mar 5, 2025 | — | Form 144 ↗ |
| Mar 5, 2025 | Bodenhoff Mads Officer, SENIOR VP PRINCIPAL ACCOUNTING… | ASND Ascendis Pharma A/S | 2,254 | $349.4K | — | Mar 5, 2025 | — | Form 144 ↗ |
| Mar 4, 2025 | Hartvig Camilla Harder Officer, EXECUTIVE VP AND CHIEF COMMERC… | ASND Ascendis Pharma A/S | 2,222 | $338.0K | 10b5-1 | Mar 4, 2025 | — | Form 144 ↗ |
| Mar 4, 2025 | Bodenhoff Mads Officer, SENIOR VP PRINCIPAL ACCOUNTING… | ASND Ascendis Pharma A/S | 2,828 | $430.2K | 10b5-1 | Mar 4, 2025 | — | Form 144 ↗ |
| Mar 4, 2025 | William Fairey Director | ASND Ascendis Pharma A/S | 1,006 | $153.0K | 10b5-1 | Mar 4, 2025 | — | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 7:04 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances